Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0QH7H
|
||||
| Former ID |
DIB015420
|
||||
| Drug Name |
AMP-579
|
||||
| Synonyms |
RPR-100579; (1S,2R,3S,4R)-4-[7-[1(R)-(3-Chloro-2-thienylmethyl)propylamino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H28ClN5O3S
|
||||
| Canonical SMILES |
CCNC(=O)[C@H]1C[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N[C@H](CC<br />)Cc4sccc4Cl)ccnc23
|
||||
| InChI |
1S/C22H28ClN5O3S/c1-3-12(9-17-14(23)6-8-32-17)27-15-5-7-25-21-18(15)26-11-28(21)16-10-13(19(29)20(16)30)22(31)24-4-2/h5-8,11-13,16,19-20,29-30H,3-4,9-10H2,1-2H3,(H,24,31)(H,25,27)/t12-,13+,16-,19-,20+/m1/s1
|
||||
| InChIKey |
DNPNXAXAKNFJDD-GFOALDQYSA-N
|
||||
| CAS Number |
CAS 143395-98-6
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A2a receptor | Target Info | Modulator | [2] | |
| Adenosine A1 receptor | Target Info | Modulator | [2] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholismhsa04022:cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Reactome | NGF-independant TRKA activation | ||||
| Adenosine P1 receptors | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolismR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| Monoamine Transport | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| References | |||||
| REF 1 | Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May; 1808(5): 1290-1308. | ||||
| REF 2 | Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53. Epub 2004 Jul 22. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.